Skip to content
  • Our Focus
  • About Us
  • Resources

    • Browse our latest resources

    • NewsroomKeep up with our latest news.
    • PublicationsLearn more about our science.
    • Trail NotesInsights from our leadership team
    • Cliffs NotesDownloadable, infographics and more.
  • Careers
  • Contact
  • Careers
  • CLINICALTRIALS.GOV
  • The Crestone Study
    •
    Cliffs Notes

    Infographic: PDX Models and Precision Oncology

    February 22, 2021March 3, 2021
    by Elevation Oncology
    Preclinical Diagnostics Genomic Testing Gene Fusions Data Research NRG1 fusion Partnership

    We recently shared preclinical data on seribantumab in NRG1 fusion PDX models at EORTC-NCI-AACR 2020. Here’s a closer look at what PDX models are, and why they’re such important tools for developing precision medicines for cancer:

    Save this Infographic
    Download PDF
    Share
    Other Related Resources
    October 26, 2020

    Publications

    The anti-HER3 monoclonal antibody seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with NRG1 rearrangements

    Presented at EORTC-NCI-AACR 2020

    Presenting Author: Igor Odintsov, MD; Memorial Sloan Kettering Cancer Center

    Read More
    November 13, 2020

    Trail Notes

    NRG1 fusions, a (PDX) model challenge Read More
    October 26, 2020

    Cliffs Notes

    Spotlight on data: Seribantumab in preclinical NRG1 fusion models Read More
    October 26, 2020

    Newsroom, Press Releases

    Elevation Oncology Announces the Presentation of Preclinical Data on the Specific Inhibition of HER3 to Block NRG1 Fusion Signaling Read More
    Cliffs Notes
    • Our Focus
    • About Us
    • Careers
    • Contact
    • Terms
    • Privacy
    • ClinicalTrials.gov
    • The Crestone Study